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Abbreviations: NCDs: non-communicable diseases; ICRP: International Cancer Research Partnership; 
EU: European Union; HPV: human papillomavirus; WHO: World Health Organization; EORTC: 
European Organisation for Research and Treatment of Cancer; CCC: Comprehensive Cancer Centres;  
BBMRI-ERIC: Biobanking and BioMolecular resources Research and Infrastructure – European 
Research Infrastructure Consortium; BBMRI-LPC: Biobanking and BioMolecular resources Research 
and Infrastructure – Large Prospective Cohorts.  
 
Abstract 
The case for cancer prevention in Europe is the same as for all other parts of the world. The number 
of cancers is increasing, driven by demographic change and evolution in the exposure to risk factors, 
while the cost of treating patients is likewise spiralling. Estimations suggest that around 40% of 
cancers in Europe could be prevented if current understanding of risk and protective factors was 
translated into effective primary prevention, with further reductions in cancer incidence and 
mortality by screening, other approaches to early detection, and potentially medical prevention. 
However, the infrastructure for cancer prevention tends to be fragmented between and within 
different countries in Europe. This lack of a coordinated approach recently led to the foundation of 
Cancer Prevention Europe (Forman et al. 2018), a collaborative network with the main aims of 
strengthening cancer prevention in Europe by increasing awareness of the needs, the associated 
required resources, and reducing inequalities in access to cancer prevention across Europe. This 
article showcases the need for strengthening cancer prevention and introduces the objectives of 
Cancer Prevention Europe and its foreseen future role in reducing the European cancer burden. 
 
The case for prevention 
The case for cancer prevention in Europe, at a fundamental level, is the same as for all other parts of 
the world. The number of cancers is increasing, driven by demographic change and evolution in the 
exposure to risk factors, while the cost of treating patients is likewise spiralling. The most recent 
report on 25 cancers in the 40 countries of Europe estimated 3.91 million new cases (excluding non-
melanoma skin cancer) and 1.93 million deaths in 2018 (Ferlay et al. 2018). This corresponds to an 
age-standardized cancer incidence rate of 374 cases per 100,000 population (European age 
standard), with some variation across the countries (Figure 1). In the EU-28, the estimated number 
of new cases of cancer was approximately 1.6 million in males and 1.4 million in females, with 
790,000 men and 620,000 women dying from the disease. The number of cancers on the continent is 
projected to increase to 4.75 million cases and 2.55 million deaths in 2040 primarily as a result of 
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population aging and growth (GCO 2018). This represents an overall increase in mortality of 32%, i.e. 
an additional 620,000 people dying each year. 
In Europe, other non-communicable diseases (NCDs), including cardiovascular disease, diabetes, and 
chronic respiratory illnesses, also place a heavy burden on health systems, but here progress in 
treating or controlling the diseases in their early phases has been more effective. The complexity and 
diversity of cancer, occurring as it does in different organs and cell types with associated intra-
tumour heterogeneity, implies the need for a multitude of tests for early detection coupled with 
treatments tailored to specific types of cancers.  This is quite different in scope to other NCDs where, 
for example, progress has been made in controlling blood pressure or cholesterol through the 
development of widely applicable drugs, such as anti-hypertensives and statins.  The result is that 
cancer is now the leading cause of premature death (defined as death below the age of 70 years) in 
28 of the 40 countries of Europe and is the second most common in the remaining countries (Ferlay 
et al. 2018). Furthermore, while there is good news in terms of improvement in cancer survival in 
Europe, cancer survivorship also entails long-term follow-up and care with the attendant demands 
on health services (Allemani et al. 2018). 
In contrast to the dominance of cancer in terms of disease burden in Europe and the high proportion 
of cancers attributable to modifiable factors, the majority of cancer research investment continues 
to be made in basic science and clinical translational research with the focus on the development of 
new therapies or improving treatment. In addition, investment in primary prevention has often been 
neglected partly because the results are difficult to recognize in individuals and its impact may take 
several decades to emerge. For example, in data provided by the International Cancer Research 
Partnership for the United Kingdom (UK), France and The Netherlands (for 2014 and 2015, the last 
years with complete data), 57% of funding from government and non-government organization 
sectors was assigned to therapy-oriented biology and drug development with 7% to prevention and 
13% each to aetiology and to early detection, diagnosis and prognosis (ICRP 2018.). Private sector 
funding of cancer research has little incentive to invest in prevention, besides research related to 
vaccine and early detection technology development, and thus the balance is further skewed if an 
analysis of all funding sources is conducted. Exciting developments in precision oncology drugs and 
immunotherapy promise a step-change improvement in cancer survival, but come at high cost and 
by definition benefit a few sub-sets of patients.  
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It is not alarmist to conclude that the status quo in relation to cancer control measures threatens the 
sustainability of health care provision in Europe. The economics of a primary focus on cancer 
treatment do not make for cost-effective cancer control policies unless aligned to public health 
strategies for prevention. 
There are evidence-based and cost-effective preventive interventions available for cancer, based on 
prior research into aetiology. In addition, primary prevention offers the most advantageous 
approach to reducing cancer and other NCDs by reducing common risk factors and therefore 
producing important co-benefits for health (Espina et al. 2013). Primary prevention coupled with 
secondary prevention through early detection of pre-malignancy can avoid not only medical costs, 
but also the considerable physical, social, and psychological co-morbidities and suffering associated 
with most cancer treatments. Tertiary prevention of cancer recurrence among survivors adds further 
weight to a balanced approach to prevention and treatment. Indeed from a health, social, and 
economic viewpoint, a more systematic and structured approach to cancer prevention in Europe is a 
logical necessity.  
Any strategic approach to cancer prevention in Europe needs to recognise heterogeneity across the 
continent, both in the pattern of cancers and the stage of implementation of the available 
preventive interventions. In Bulgaria, Romania, and some Baltic States, for example, the prevalence 
of persistent HPV infection is rising in the absence of HPV vaccination, and as a consequence of this 
and of the lack of effective screening, cervical cancer incidence rates are on the increase (Arbyn et 
al. 2017). In France, the HPV vaccination rate among young girls is only around 25%. Europe has the 
highest smoking rates of any WHO region but this masks considerable differences (EURO 2017). 
While countries like Sweden, Iceland, Ireland, Norway, and the UK have achieved significant 
reductions in smoking in recent years, other countries like Hungary and Cyprus have seen little 
change. Alcohol consumption is the second most common cause of cancer in France (Shield et al. 
2017), after smoking, with this risk factor having been under-emphasised as a priority for cancer 
prevention, as has avoidance of excess exposure to sunlight. The most recent report on 
implementation of cancer screening programmes for cervix, breast, and colorectal cancers shows a 
general improvement in the European Union, but nevertheless reveals marked differences among 
countries (Ponti et al. 2017).   
Recent detailed estimates in France, the UK, and Germany suggest that around 40% of cancers in 
Europe could be prevented if current understanding of established risk and protective factors was 
translated into effective primary prevention (Brown et al. 2015, Soerjomataram et al. 2018, Mons et 
al. 2018, Behrens et al. 2018, Gredner et al. 2018).  Cancer screening and other approaches to early 
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detection of pre-malignant lesions or surveillance among very high-risk groups can also contribute to 
reduce cancer incidence and mortality. Interventions such as physical activity among breast cancer 
survivors offer exciting opportunities to improve prognosis and quality of life among cancer survivors 
(Friedenreich et al. 2017). In due course, additional benefits may come from medical prevention 
among cancer survivors or through surveillance of high-risk individuals or groups in the general 
population (Cuzick 2017). 
Successful cancer prevention is not a trivial challenge. It requires considerable commitment to 
implementation at national level through strategies that reach all segments of society. Solutions 
cannot be aimed only at individuals (as characterised by the European Code against Cancer (Schuz et 
al. 2015)) but must be supported by legislative and regulatory measures. Some exposures, notably 
reduction in exposure to air pollution, require international agreements in order to be truly 
effective. A cautionary note is merited in some areas of prevention where “more is less”, either 
because approaches being implemented are not evidence-based or because the magnitude of any 
effect would be insignificant. An example is the over-diagnosis and over-treatment of some cancers 
e.g. for example, small papillary thyroid cancers (Vaccarella et al. 2016). 
Notwithstanding the challenges in implementing preventive interventions, the prize is of great value 
and complementary to that of treating and caring for cancer patients more effectively. Reducing the 
number of patients developing cancer should result in greater resources being available to treat 
those patients with the most effective therapies available. 
 
The need for strengthening cancer prevention in Europe 
Cancer prevention has a broad scope. As mentioned above, the field encapsulates surveillance and 
descriptive data (e.g. incidence, mortality, survival, and prevalence; economic analyses including 
cost-effectiveness; prevalence of exposure to risk factors, etc.) as well as the areas of primary, 
secondary, and tertiary prevention. Prevention may be aimed at the whole population e.g. as with 
anti-smoking legislation, or at specific high-risk sub-groups, for example, surveillance colonoscopy in 
patients previously diagnosed with polyps, with aspirin being under consideration for different at-
risk groups. 
The broad scope of prevention is naturally matched by a broad scope of practitioners. Indeed the full 
range of prevention activities relies on an interdisciplinary approach that encompasses 
epidemiology, cancer registries, basic and applied laboratory sciences, public health, general 
practice, clinical science, health services, health psychology, the social sciences, and implementation 
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science among other disciplines. The contribution of social sciences, humanities, and anthropology is 
particularly needed. It is now perceived that the traditional health promotion/health education 
paradigm based on individual advice (e.g. from physicians or nurses), though laudable, is not 
sufficient and tends to create social disparities in terms of efficacy. Social sciences, and particularly 
anthropology, help to embed behavioural changes in cultural contexts. This is particularly true, for 
example, of obesity, which is not equally perceived in all social strata and cultural subgroups. Indeed 
all cancer control initiatives should undergo a thorough and ongoing evaluation as to whether they 
diminish or exacerbate social inequalities within and between countries (Vaccarella et al. 2018).  
The broad scope of disciplines brings with it a broad scope of institutions and professional 
organizations. Perhaps partially as a result of this situation, at institutional or even national level the 
infrastructure for cancer prevention tends to be fragmented. There are few exemplars of 
“prevention centres” analogous to primary, secondary, or tertiary care centres. Likewise, there are 
few centres of research excellence in prevention, unlike the many world class cancer treatment 
centres in Europe. International collaborative consortia (e.g. the European Organisation for Research 
and Treatment of Cancer - EORTC) are the norm in the employment of clinical trials in development 
of new treatments, whereas the absence of analogous structures is one factor which inhibits the 
development of world class prevention research.  
Most often there is a separation between centres of expertise in cancer prevention and in cancer 
treatment, reflected in differences in organisational responsibility, perception, and culture. Health 
care is usually the political responsibility of Government (Ministry of Health or equivalent, and their 
respective health authorities), performed by health care professionals and undertaken in hospitals 
and primary care centres. These parameters of responsibility, expertise and location are 
considerably more complicated for prevention. Many of the above-mentioned disciplines required 
for cancer prevention are to be found, for example, in institutes of public health, universities, 
charities, and health and non-health related government departments or cancer centres. Linkages in 
the context of cross-sectorial initiatives or strategies such as “Health in All Policies” would make 
good sense in cancer prevention (Espina et al. 2013). 
Successful coordination of cancer prevention in Europe requires long-term vision, a dedicated 
research agenda, and strategically targeted funding. It also requires a sustainable infrastructure and 
cooperation between countries and programmes to fill gaps in the evidence base for prevention, to 
avoid common pitfalls in implementation and to share capacity for research training and quality 
improvement. Comprehensive Cancer Centres (CCCs) are in an excellent position to offer a pan-
European cancer research infrastructure, linking treatment and prevention with research and 
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education, and thus connecting research with the healthcare systems (Celis & Pavalkis 2017). For all 
these reasons, the initiative was taken within the FP7 Eurocan Platform project to create a network 
for strengthening cancer prevention in Europe, called “Cancer Prevention Europe” (see 
http://www.cancerpreventioneurope.eu). Close collaboration between Cancer Core Europe and 
Cancer Prevention Europe, involving other organisations and stakeholders active in cancer 
prevention and treatment, will ensure that developments in understanding the causes of cancer will 
translate both into clinical and population-based innovations and practices, addressing the whole 
cancer continuum in partnership. 
 
The objectives of Cancer Prevention Europe 
Cancer Prevention Europe originated in a general and collective recognition that cancer prevention 
in Europe is fragmented and lacks an overall strategy. In addition, the requirement for a more 
integrated approach in conjunction with related innovations in the area of cancer treatment was 
clear: the formation of Cancer Core Europe (Celis & Pavalkis 2017) offered an opportunity in this 
respect.   
Cancer Prevention Europe was created, therefore, initially as a consortium of a number of leading 
European research institutions [Cancer Research UK, London, UK; Danish Cancer Society, 
Copenhagen, Denmark; European Institute of Oncology, Milan, Italy; German Cancer Research 
Centre, Heidelberg, Germany; Imperial College London, London, UK; Karolinska Institute, Stockholm, 
Sweden; UK Therapeutic Cancer Prevention Network, Leicester, UK; World Cancer Research Fund 
International, London, UK/Wereld Kanker Onderzoek Fonds, Amsterdam, The Netherlands] 
committed to prioritising cancer prevention. Each consortium member made a financial contribution 
to fund a small secretariat at IARC and to initiate specific strategic areas of collaborative research. A 
full description of the manifesto of the consortium has recently been published (Forman et al. 2018).  
In brief, a number of objectives have emerged from this first phase in the development of the Cancer 
Prevention Europe initiative: 
 to provide an infrastructure for coordinated cancer prevention research at the European 
level which is sustainable and open to expansion with new members over time; 
 to communicate and disseminate to policymakers the opportunities and benefits of available 
preventive interventions; 
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 to formulate the scope of prevention research and to advocate for increased investment in 
this area;  
 to drive innovative inter-disciplinary research, including the opportunities afforded by 
advances in understanding cancer aetiology; 
 to bridge the identification of risk factors through to the development and implementation 
of preventive interventions; 
 to enable the translation of research on preventive interventions into effective cancer 
policy; 
 to provide a platform for advocacy for cancer prevention among a wide set of stakeholder 
engagement, including citizens and patients. 
The development of an alliance of organizations focused on cancer prevention also promises to 
provide a focal point for development of professional training and career development in an area 
where no simple career pathway is evident. This initiative should consider the provision of dedicated 
academic courses and qualifications in the area of cancer prevention, with teaching provided from 
among the different disciplines implicated. 
There are a number of challenges facing Cancer Prevention Europe. First, the consortium needs to 
identify a mechanism within the European funding tools to obtain the required financing to fulfil its 
objectives. One option is the new “mission-orientated” research agenda but this is not the only 
mechanism that can be envisaged. For now the commitment is high among the founder members of 
the consortium but accessible resources remain limited. Second, Cancer Prevention Europe needs to 
encompass innovative research and collaboration across the whole of Europe, including the specific 
challenges of inequalities both between and within countries. The consortium is thus seeking 
mechanisms to broaden participation and achieve this critical mass without diluting commitment 
and quality. Third, Cancer Prevention Europe recognizes the importance of an integrated approach 
that encompasses prevention and treatment in cancer research and cancer control: this requires a 
European-level vision that carries all of these areas forward to deliver sustainable cancer services. 
 
The next steps for Cancer Prevention Europe 
The ambition of Cancer Prevention Europe is to transform the current research landscape through 
this new interdisciplinary consortium of institutes and organisations.  The consortium aims to 
conduct innovative world class research capable of translation into effective cancer prevention 
guidelines and policies at national and international level. Cancer Prevention Europe offers an 
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integrated infrastructure capable of delivering such high quality research in a collaborative, 
interdisciplinary manner.  
The innovative science behind cancer prevention offers an opportunity to add value to a number of 
prior investments at the level of the European Commission, including large collaborative research 
studies e.g. on the exposome (e.g. Exposomics, HELIX) and research infrastructure investments, 
including biobanks (BBMRI-ERIC) and large population-based cohort studies of chronic diseases (e.g. 
BBMRI-LPC), which all provide platforms for research on cancer prevention.  
Inherent to the philosophy of Cancer Prevention Europe is the sharing of resources (including 
existing research platforms, biospecimen repositories, cohorts etc.); the sharing of data (enabling 
multicentre, trans-national research projects); and the sharing of information (through the creation 
of a central repository of information pertinent to cancer prevention). Suitable and acceptable legal 
frameworks would be established within Cancer Prevention Europe to permit information exchange, 
to monitor regulations, and to highlight potential and actual barriers to progress through 
implemented legislation. 
The new mission-oriented approach to European research investment provides one major 
opportunity to enhance cancer prevention and better align the investments in research with the 
needs of Member States in relation to cancer control, thus optimising benefits for all European 
citizens. This approach aligns well with the recent WHO European Health Report 2018 (EURO 2018) 
and the World Health Assembly 2017 resolution on cancer prevention and control (WHO 2017).  
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Figures 
Figure 1. Age-standardized cancer incidence rate in European countries (both sexes combined, 
excluding non-melanoma skin cancer, using World Standard Population)  
 
 
 
 
 
